https://dash.harvard.edu/entities/publication/73120379-27ad-6bd4-e053-0100007fdf3b
EZH2 inhibition sensitizes BRG1 and EGFR mutant lung tumors to TopoII inhibitors
SUMMARY Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related death worldwide1. Chemotherapies such as the topoisomerase II inhibitor...